The prognostic differences and the effect of postmastectomy radiotherapy between post‐chemotherapy ypT1‐2ypN1 and de novo pT1‐2N1 breast cancer

The prognosis and the value of postmastectomy radiotherapy (PMRT) between post‐chemotherapy ypT1‐2ypN1 and de novo pT1‐2N1 breast cancer (BC) remain controversial. We aimed to evaluate the prognostic differences and the effect of PMRT between the two patient subsets.

[1]  Cheng Xu,et al.  Practical Model to Optimize the Strategy of Adjuvant Postmastectomy Radiotherapy in T1-2N1 Breast Cancer With Modern Systemic Therapy , 2022, Frontiers in Oncology.

[2]  Cong Jiang,et al.  Correlation analysis of lymphocyte-monocyte ratio with pathological complete response and clinical prognosis of neoadjuvant chemotherapy in patients with breast cancer , 2022, Translational oncology.

[3]  R. Kimmig,et al.  Systematic Evaluation of HLA-G 3’Untranslated Region Variants in Locally Advanced, Non-Metastatic Breast Cancer Patients: UTR-1, 2 or UTR-4 are Predictors for Therapy and Disease Outcome , 2022, Frontiers in Immunology.

[4]  Yiding Chen,et al.  Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in cT1-2N+ Breast Cancer Patients: A Single Center Experience and Review of Current Literature , 2022, Frontiers in Oncology.

[5]  H. Park,et al.  The Impact of Post-Mastectomy Radiotherapy on Survival Outcomes in Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy , 2021, Cancers.

[6]  T. Luo,et al.  Postmastectomy radiation therapy and survival outcome in older patients with T1-2N1 breast cancer , 2021, Breast.

[7]  Su Ssan Kim,et al.  Effect of Postoperative Radiotherapy after Primary Tumor Resection in De Novo Stage IV Breast Cancer: A Multicenter Retrospective Study (KROG 19-02) , 2021, Cancer research and treatment.

[8]  Wanqing Chen,et al.  Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020 , 2021, Chinese medical journal.

[9]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[10]  Szu-Yuan Wu,et al.  Breast-conserving surgery with or without irradiation in women with invasive ductal carcinoma of the breast receiving preoperative systemic therapy: A cohort study , 2020, Breast.

[11]  Liangfang Shen,et al.  Postmastectomy radiotherapy based on pathological nodal status in clinical node-positive stage II-III breast cancer treated with neoadjuvant chemotherapy. , 2020, International journal of radiation oncology, biology, physics.

[12]  E. Winer,et al.  Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Ping Wang,et al.  Locoregional recurrence-associated factors and risk-adapted postmastectomy radiotherapy for breast cancer staged in cT1-2N0-1 after neoadjuvant chemotherapy , 2018, Cancer management and research.

[14]  A. Quick,et al.  Heterogeneity in Outcomes of Pathologic T1-2N1 Breast Cancer After Mastectomy: Looking Beyond Locoregional Failure Rates , 2018, Annals of Surgical Oncology.

[15]  M. Morrow,et al.  Most Breast Cancer Patients with T1-2 Tumors and One to Three Positive Lymph Nodes Do Not Need Postmastectomy Radiotherapy , 2018, Annals of Surgical Oncology.

[16]  Mike Clarke,et al.  Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials , 2018, The Lancet. Oncology.

[17]  M. Morrow,et al.  Axillary Micrometastases and Isolated Tumor Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast Cancer , 2017, Annals of Surgical Oncology.

[18]  T. Sarigoz,et al.  Role of postmastectomy radiation therapy in breast cancer patients with T1–2 and 1–3 positive lymph nodes , 2016, OncoTargets and therapy.

[19]  Kristine R Broglio,et al.  Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. , 2016, JAMA oncology.

[20]  Lin Zhao,et al.  Prognostic analysis in a Chinese population with T1‐2N1 breast cancer: Did patients with 1 or 2, and 3 positive axillary lymph nodes have similar survival outcomes? , 2015, Journal of surgical oncology.

[21]  J. Bogaerts,et al.  Tumour size is the only predictive factor of distant recurrence after pathological complete response to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: a sub-study of EORTC 10994/BIG 1-00 phase III trial. , 2015, European journal of cancer.

[22]  EBCTCG (Early Breast Cancer Trialists' Collaborati.  Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials , 2014, The Lancet.

[23]  T. Kinoshita,et al.  Locoregional recurrence risk factors in breast cancer patients with positive axillary lymph nodes and the impact of postmastectomy radiotherapy , 2013, International Journal of Clinical Oncology.

[24]  C. Reddy,et al.  Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1-3 positive lymph nodes treated with modern systemic therapy. , 2012, International journal of radiation oncology, biology, physics.

[25]  D. Tiezzi,et al.  Taxane-based chemotherapy enhances response to neoadjuvant treatment for stage II and III breast cancer , 2011, Medical oncology.

[26]  S. Paik,et al.  Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  C. Gross,et al.  Postmastectomy radiation and survival in older women with breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Collins,et al.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[29]  R. Kim,et al.  Current and future roles of neoadjuvant chemotherapy in operable breast cancer. , 2005, Clinical breast cancer.

[30]  T. Buchholz.  Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial , 2005 .

[31]  J. Ioannidis,et al.  Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. , 2005, Journal of the National Cancer Institute.

[32]  John J Spinelli,et al.  Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. , 2005, Journal of the National Cancer Institute.

[33]  B. Rasmussen,et al.  Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial , 1999, The Lancet.

[34]  Anthony Howell,et al.  Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. , 1995, The New England journal of medicine.

[35]  L. Pierce,et al.  Postmastectomy radiotherapy in the management of operable breast cancer , 1994, Cancer.

[36]  S. Masuda,et al.  Role of Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer Patients: A Study from the Japanese Breast Cancer Registry , 2019, Annals of Surgical Oncology.

[37]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .